Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Outpost Medicine

Request full access

Developing novel therapeutics for urologic and gastrointestinal disorders

London, United KingdomFounded 2016Biotech & Life Sciences

About Outpost Medicine

Outpost Medicine was a biopharmaceutical company established to develop and commercialize new treatments for urologic and gastrointestinal disorders. The company, now listed as no longer active, was formed in March 2016 as a joint venture between Takeda Pharmaceutical and the venture capital firm Frazier Healthcare Partners. It was co-founded by two venture partners from Frazier: Dr. Tachi Yamada, a gastroenterologist with an extensive background leading research at major pharmaceutical companies like Takeda and GlaxoSmithKline, and David Socks, a seasoned healthcare entrepreneur. The business model centered on in-licensing promising clinical-stage assets to develop them further.

Upon its launch, Outpost Medicine secured the exclusive worldwide rights from Takeda to develop OP-233, a clinical-stage compound for treating stress urinary incontinence (SUI). This initiative was supported by an initial $41 million Series A financing round led by Frazier Healthcare Partners, with participation from Adams Street Partners, Novo A/S, and Vivo Capital. However, the company later discontinued the OP-233 program in November 2017 due to unspecified safety issues discovered during human trials. Concurrently, Outpost announced an extension of its Series A round, bringing the total to $61 million, with Takeda's venture arm joining as a new investor. These funds were redirected to advance a new lead candidate, OP-687, an oral therapy intended for overactive bladder (OAB) and irritable bowel syndrome (IBS). The company further expanded its pipeline in May 2018 by licensing a preclinical compound from Arena Pharmaceuticals aimed at genitourinary disorders.

The company's leadership evolved, with Scott Byrd, a former Eli Lilly executive, appointed as CEO in November 2017 to steer the new clinical focus, succeeding interim CEO David Socks. Outpost established a dual-location operational structure, with its headquarters and U.S. operations in Indianapolis, while its scientific and medical teams were based in London. Despite raising a total of $97 million over two funding rounds and assembling an experienced team, the company ultimately ceased operations.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Dealroom signal
25.0/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Developer Tools, Biotechnology, Gastroenterology, Biotech and Pharma, uk is8 life sciences, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B
Links
Website

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES AOther financing Nov 2017 $20M $80M Adams Street Partners · Frazier Healthcare Partners · Takeda Ventures · Novo Holdings ↗
SERIES AOther financing Mar 2016 $41M $164M Novo Holdings · Vivo Capital · Adams Street Partners · Takeda Ventures —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Outpost Medicine website traffic

Latest recorded traffic for Outpost Medicine is 270 monthly website visits, up 17.4% over the last three months.

Latest monthly visits270 3-month web change+17.4%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Outpost Medicine in the London ecosystem

Live from Dealroom

The Outpost Medicine office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

5 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A5 investors entered at this stage

Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇬🇧 United Kingdom · London HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Outpost Medicine on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Outpost Medicine’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.